Pam McAllister attended the 2010 GI Cancers Symposium in Orlando on a C3 scholarship.
Pam is one of the original colorectal cancer research advocates and has been involved with research advocacy activities for well over a decade. She serves on numerous research panels and has co-authored many articles including the 2008 American Cancer Society Screening Guidelines and the ASCO Clinical Opinion on Testing for KRAS Mutations.
Here is the first of three articles she has written for C3’s Research and Treatment News about what she learned at the Orlando meeting.
Last year we learned that Avastin® (bevacizumab) was not effective in increasing disease free survival in stage III colon cancer except for a possible small transient benefit that disappeared soon after the drug was discontinued. Read the rest of this entry »